Global Haemodialysis Equipment Market is segmented by Product Type (Peritoneal Dialysis Catheter, Chronic Haemodialysis Catheter, Acute Haemodialysis Catheter), By Modality (In-Centre Haemodialysis, Home Haemodialysis), By End-User (Hospitals, Dialysis Centres, Home Care), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) ā Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Haemodialysis Equipment Market Size
The Global Hemodialysis Equipment Market reached US$ 9.684.48 million in 2023 and is expected to reach US$ 14,151.99 million by 2031, growing at a CAGR of 4.9% during the forecast period 2024-2031.
Haemodialysis is a medical procedure that involves the removal of fluids and waste products from the blood. This is accomplished by using a dialysis machine and a dialyzer. It is used to treat both acute and chronic kidney failure. The haemodialysis equipment market is driven by the number of End-Stage Renal Disease (ESRD) patients owing to the growing prevalence of diabetes, hypertension, and an increasingly large elderly population. ESRD is the most severe form of renal failure where kidneys permanently cease to function and the affected person loses the adequate kidney function necessary to sustain life.
Market Summary
|
Metrics |
Details |
|
Market CAGR |
4.9% |
|
Segments Covered |
By Product Type, By Modality, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Market Dynamics
The major drivers fueling the growth of the market are the increasing number of ESRD patients and a significant rise in the number of dialysis centers. The restraints that pull down the haemodialysis market are rising cases of kidney transplants and the advent of newer approaches like artificial kidneys.
The increasing number of ESRD (end-stage renal disorder) patients require continuous support via dialysis, hence driving market growth
ESRD patients have been steadily increasing across the world. They are the biggest end-users of dialysis, as their kidneys have lost much of their functionality. The burden of ESRD will increase in the United States population through 2030 due to demographic, clinical, and lifestyle shifts in the population and improvements in RRT. Planning for ESRD resource allocation should allow for substantial continued growth in the population of patients with ESRD. Future interventions should be directed to preventing the progression of CKD to kidney failure. The increase in ESRD incidence rates within age and race groups have leveled off and/or declined in recent years, but our model indicates that population changes in age and race distribution, obesity and diabetes prevalence, and ESRD survival will result in an XX% increase in the crude incidence rate from 2020 to 2030.
An increase in the number of kidney transplants will reduce the haemodialysis market share
People with kidney failure need dialysis or a kidney transplant to stay alive. After kidney transplantation, they no longer require dialysis to survive. The number of kidney transplants increased by XX% in the year 2019 and will show strong growth. Multiple factors could explain this increase. The narcotics overdose epidemic is unending and has created the demand for almost one-third of these transplants. Another reason for the upward trend is the increased use of organs harvested from patients following cardiac death and not just from those who suffer brain death. Organs donated after cardiac death account for about 20% of organ donations. In addition, organ procurement organizations have excelled at identifying donors, and have broadened the population of donors that they are willing to consider for donation. Those organs which were not considered in the past are now acceptable. Even after an increase in the supply of kidneys, the demand is still unmet, with XX patients awaiting kidney transplants at any given moment in North America.
COVID-19 Impact Analysis
The global pandemic COVID-19 had a disproportionate effect on maintenance dialysis patients and their health care providers. It affected the market growth for haemodialysis equipment. COVID-19 has resulted in the untimely demise of many patients with preexisting medical co-morbidities, such as diabetes, heart problems, renal disorders, etc. Infection with SARS-CoV-2 is grave for many dialysis patients, with case fatality ratios in the 10-30% range to date among cases diagnosed by selected testing. The most recent data have not shown any improvement in case fatality ratios to date. These patients require dialysis, and a reduction here has resulted in shrinkage of markets for dialysis. Nevertheless, dialysis centers are taking extra precautions to ensure that the virus does not spread to patients who require dialysis.
Market Segment Analysis
Peritoneal Dialysis is Projected to Drive the Global Dialysis Market
Among the dialysis types, haemodialysis equipment segment holds a major share of the dialysis equipment market. Additionally, the peritoneal dialysis equipment segment is projected to register comparatively higher growth in the global market. A higher level of patient comfort, a dramatic reduction in treatment cost, and the high operating flexibility of peritoneal dialysis are expected to fuel the growth of the peritoneal dialysis during the forecast period. The higher prevalence of end-stage renal disease and chronic kidney disease in emerging nations represents a huge demand for peritoneal dialysis.
Moreover, the proven efficiency of peritoneal dialysis over haemodialysis in terms of cost, session time, and equipment functioning is anticipated to increase the adoption of peritoneal dialysis in emerging nations. Based on the dialysis equipment type, the haemodialysis equipment market segment includes haemodialysis equipment and peritoneal dialysis equipment. The haemodialysis equipment industry is expected to hold a considerable share in the market during the forecast period. Based on the end-user, the global dialysis equipment market segment includes dialysis centers & hospitals, and home healthcare. Hospitals & dialysis centers are projected to hold a considerable share of the global market.
Market Geographical Share
A rapidly increasing number of dialysis centers and hospitals in emerging nations combined with an increasing number of patient treatments are projected to increase the installments of new dialysis equipment are anticipated to boost the growth of the global dialysis equipment market by 2028.
Higher Prevalence of End-Stage Renal Disease and Chronic Kidney Disease to Favor Growth in the Asia Pacific
Asia Pacific generated revenue of USD XX Million in 2020 and is expected to dominate the market throughout the forecast period. The higher incidence and prevalence of end-stage renal disease is leading to increasing adoption of dialysis equipment, resulting in the growth of the dialysis equipment market size in the Asia Pacific. Moreover, a higher pace of infrastructure development and increasing awareness and education amongst patients are creating a favorable environment to utilize and install dialysis equipment in emerging nations.
North America is anticipated to be the second most prominent region in terms of revenue by 2025. In Europe, the rapidly increasing prevalence of end-stage renal disease is anticipated to offer a lucrative opportunity for the growth of the market during the forecast period.
Haemodialysis Equipment Market Companies and Competitive Landscape
Some of the key players in the market are Fresenius Medical Care, DaVita Healthcare Partners, Baxter International, B. Braun Melsungen, Nipro Corporation, Diaverum Deutschland GmbH, Nikkiso Co. Ltd., and NxStage Medical.
The major companies in the market are focusing high on R&D, product innovation, an extension of the existing product line, and looking to strengthen the market presence by geographical expansion. For instance, in January 2019, Baxter International Inc. got FDA approval for its clinical trial on an on-demand peritoneal dialysis solution generation system. The new system offers a good platform for patients to perform peritoneal dialysis at home. In September 2017, Fresenius Medical Care started a new manufacturing facility in Malaysia. The strategic move was taken by the company to accelerate the production of advanced continuous ambulatory peritoneal dialysis materials.
Key Companies to Watch
Fresenius Medical Care
Overview: Fresenius Medical Care is one of the leading players operating in the global dialysis equipment market volume. The company is estimated to retain its position in the forecast duration owing to its innovative product offerings, efficient customer reach, and strong brand presence. At present, Fresenius Medical Care together with Baxter holds over half of the market share in terms of revenue. They also hold a considerable share of the peritoneal dialysis market.
Product Portfolio: It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patientās residence. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services.
